CUPID (64Cu-TLX592 phase I PK, biodistribution and dosimetry): A proof-of-concept study of TLX592-targeted alpha therapy in prostate cancer.64Cu-TLX592 refers to a radioactive compound that consists of two components:
64Cu: This is the radioactive isotope of copper (copper-64), which is commonly used in positron emission tomography (PET) imaging and radiotherapy. It decays by emitting positrons, allowing for detection via PET scanning. The isotope has a half-life of around 12.7 hours, making it useful for medical imaging because of its relatively short decay time.
TLX592: This is likely the chemical compound or molecular targeting agent that is labeled with the 64Cu isotope. It is possible that TLX592 is a drug, antibody, or peptide designed to target specific receptors or cells within the body, for instance, to locate or treat certain types of cancer or other diseases. In radiolabeled drug development, attaching a radioactive isotope like 64Cu to a targeting molecule allows for non-invasive imaging to visualize how the drug behaves in the body.
Thus, 64Cu-TLX592 is a radiolabeled compound where TLX592 is the targeting agent, and 64Cu is the radioactive tracer used for imaging (typically with PET scans).
https://meetings.asco.org/abstracts-presentations/243196
Looks like TLX592 is supporting Cu64 imaging, i would love to see get these two company merge
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$3.80 |
Change
-0.580(13.2%) |
Mkt cap ! $1.413B | |||
| Open | High | Low | Value | Volume |
| $4.35 | $4.35 | $3.80 | $36.05M | 9.179M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 35320 | $3.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.82 | 1221 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |